Monday, January 13, 2025

The #Haemagglutinin #Gene of #Bovine-Origin #H5N1 #Influenza Viruses Currently Retains #Receptor-binding and pH-fusion Characteristics of #Avian #Host Phenotype

Abstract

Clade 2.3.4.4b H5N1 high pathogenicity avian influenza virus (HPAIV) has caused a panzootic affecting all continents except Australia, expanding its host range to several mammalian species. In March 2024, H5N1 HPAIV was first detected in dairy cattle and goats in the United States. Over 891 dairy farms across 16 states have tested positive until 25th December 2024, with zoonotic infections reported among dairy workers. This raises concerns about the virus undergoing evolutionary changes in cattle that could enhance its zoonotic potential. The Influenza glycoprotein haemagglutinin (HA) facilitates entry into host cells through receptor binding and pH-induced fusion with cellular membranes. Adaptive changes in HA modulate virus-host cell interactions. This study compared the HA genes of cattle and goat H5N1 viruses with the dominant avian-origin clade 2.3.4.4b H5N1 in the United Kingdom, focusing on receptor binding, pH fusion, and thermostability. All the tested H5N1 viruses showed binding exclusively to avian-like receptors, with a pH fusion of 5.9, outside the pH range associated with efficient human airborne transmissibility (pH 5.0 to 5.5). We further investigated the impact of emerging HA substitutions seen in the ongoing cattle outbreaks, but saw little phenotypic difference, with continued exclusive binding to avian-like receptor analogues and pHs of fusion above 5.8. This suggests that the HA genes from the cattle and goat outbreaks do not pose an enhanced threat compared to circulating avian viruses. However, given the rapid evolution of H5 viruses, continuous monitoring and updated risk assessments remain essential to understanding virus zoonotic and pandemic risks.

Source: Emerging Microbes and Infections, https://www.tandfonline.com/doi/full/10.1080/22221751.2025.2451052

_____

#USA, #California: Presumptive {#Human #H5N1} #Birdflu Case Identified In #SanFrancisco Resident

FOR IMMEDIATE RELEASE: Friday, January 10, 2025 

*** PRESS RELEASE *** 

Contact: SFDPH Media Desk: DPH.Press@sfdph.org 

SAN FRANCISCO – The San Francisco Department of Public Health (SFDPH) announced today that a presumptive case of H5N1 bird flu has been identified in a San Francisco resident

The individual is a child who experienced symptoms of fever and conjunctivitis but did not need to be hospitalized and has since fully recovered

The risk to the general public remains low as there is currently no evidence of person-to-person transmission

SFDPH is encouraging people to avoid direct contact with sick or dead birds, especially wild birds and poultry. 

Wild birds can be infected with bird flu even if they do not look sick. 

If you have found a dead bird, please contact 311. 

In addition, as bird flu continues to spread among U.S. dairy cows, SFDPH strongly recommends that individuals not consume raw milk or raw milk products, including raw cheese. 

“I want to assure everyone in our city that the risk to the general public is low, and there is no current evidence that the virus can be transmitted between people,” said Dr. Grant Colfax, Director of Health. 

“We will continue to investigate this presumptive case, and I am urging all San Franciscans to avoid direct contact with sick or dead birds, especially wild birds and poultry. Also, please avoid unpasteurized dairy products.” 

The presumptive case tested positive for H5N1 at the SFDPH Public Health Laboratory, which performed this testing as part of enhanced surveillance efforts. 

Confirmatory testing will be performed at the Centers for Disease Control and Prevention (CDC). 

The child initially tested for COVID-19, influenza, and RSV based on symptoms and tested positive for influenza A. As part of SFDPH enhanced surveillance, the specimen was subsequently tested for H5N1. 

An initial investigation by SFDPH has not revealed how the child may have contracted H5N1 bird flu

The Department is continuing to investigate, including assessing all close contacts

Again, the risk to the general public remains low as there is currently no evidence of person-to-person transmission. 

(...) Human infections with bird flu viruses are rare, and no person-to-person transmission has been detected to date in the United States. Symptoms of bird flu in humans include eye redness, coughing, fatigue, fever, and headaches. If you are experiencing these symptoms, please contact your health care provider. 

At this time, bird flu cases in California have been mild without any hospitalizations. 

Additional case information can be found at the California Department of Public Health and CDC websites.

Source: San Francisco Department of Health, https://www.sf.gov/news/presumptive-bird-flu-case-identified-san-francisco-resident

_____

Molecular #diagnosis and phylogenetic #analysis of a #MERS #coronavirus #human case in #Jordan

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) is an important zoonotic pathogen. The aim of this paper is to report one polymerase chain reaction (PCR)-positive case of MERS-CoV in a 27-year-old man who was involved in a nationwide longitudinal surveillance study of certain zoonotic diseases in Jordan including MERS-CoV. Whole-blood and nasal swab samples were collected from the man and five camels in the vicinity of his living area. The samples were subjected to enzyme-linked immunosorbent assay (ELISA) and real-time reverse-transcription PCR (RT-PCR) to detect MERS-CoV-specific antibodies and MERS-CoV genetic material, respectively. Genomic sequencing and phylogenetic analysis were also performed to detect similarities with known strains of the virus in the region. In January 2021, an ongoing surveillance study detected a MERS-CoV-positive nasal swab sample from an asymptomatic male and camels using RT-PCR. Phylogenetically, the MERS-CoV isolated in this case belonged to clade B and is clustered with other strains originating in the Arabian Peninsula. The case report represents the first PCR-positive case of MERS-CoV in an asymptomatic individual in Jordan, indicating active circulation of the virus within the population.

Source: European Journal of Public Health, https://academic.oup.com/eurpub/article/35/Supplement_1/i55/7951904

_____

#USA, #Monitoring for Avian #Influenza A(#H5) Virus In #Wastewater {Week 52/24, 01/25}

{Excerpt}

Time Period: December 29, 2024 - January 04, 2025

H5 Detection: 51 sites (17.0%)

No Detection: 249 sites (83.0%)

No samples in last week93 sites



Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/bird-flu/h5-monitoring/index.html

______

#Safety and #immunogenicity of ascending doses of #influenza A(#H7N9) inactivated #vaccine with or without MF59®

Abstract

Introduction

While it remains impossible to predict the timing of the next influenza pandemic, novel avian influenza A viruses continue to be considered a significant threat.

Methods

A Phase II study was conducted in healthy adults aged 18–64 years to assess the safety and immunogenicity of two intramuscular doses of pre-pandemic 2017 influenza A(H7N9) inactivated vaccine administered 21 days apart. Participants were randomized (n = 105 in each of Arms 1–3) to receive 3.75 μg, 7.5 μg or 15 μg of hemagglutinin (HA) with MF59® adjuvant, or 15 μg of HA unadjuvanted vaccine (n = 57, Arm 4).

Results

The three MF59 adjuvanted vaccines and the 15 μg unadjuvanted vaccine were safe and well-tolerated.

Little antibody activity was detected against the A(H7N9) vaccine antigen after the first vaccination across study Arms. After second vaccination, the three adjuvanted Arms showed increases in hemagglutination inhibition (HAI), neutralizing (Neut), and neuraminidase inhibition (NAI) geometric mean titers (GMT), peaking at 21 days post second vaccination. The percentage of participants with titer ≥1:40 and seroconversion rates for HAI were 30–43 % and 0 for the adjuvanted Arms and the unadjuvanted Arm, respectively. Antibody responses against antigenically drifted A(H7N9) strains A/Shanghai/2/2013 and A/Guangdong/17SF003/2016 showed similar trends.

Exploratory linear modeling of HAI and Neut responses post second vaccination revealed significantly lower log antibody titers among older participants (aged 35–49 and 50–64 years) compared to participants aged 18–34 years after adjusting for study vaccination, BMI, sex, and prior seasonal influenza vaccination. Post second vaccination, participants who received seasonal influenza vaccination in at least one of the two previous seasons had significantly lower log antibody titers than participants who did not.

Conclusion

Adjuvanted doses of vaccine provided higher antibody responses, on average, than the 15 μg unadjuvanted vaccine. Proportion of participants achieving seroconversion and antibody titers ≥40 remained below 50 % in all study Arm.

Source: Vaccine, https://www.sciencedirect.com/science/article/abs/pii/S0264410X24013847?via%3Dihub

_____

Sunday, January 12, 2025

#Coronavirus Disease Research #References (by AMEDEO, January 12 '25)

 


    BMJ

  1. KAST KA, Sidelnik SA, Nejad SH, Suzuki J, et al
    Management of alcohol withdrawal syndromes in general hospital settings.
    BMJ. 2025;388:e080461.
    PubMed         Abstract available


    Clin Infect Dis

  2. XIANG W, Steinbeis F, Dhindsa K, Kurth F, et al
    Predicting the risk of intensive care unit admission in patients with COVID-19 presenting in the emergency room: Development and evaluation of the CROSS score.
    Clin Infect Dis. 2025 Jan 10:ciaf006. doi: 10.1093.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  3. NAKASHITA M, Kurosawa K, Fukusumi M, Irie F, et al
    Improving the ability of psychiatric hospitals to respond to infectious disease outbreaks: lessons learned from the COVID-19 outbreak response in Ibaraki Prefecture, Japan.
    Infect Control Hosp Epidemiol. 2025 Jan 8:1-2. doi: 10.1017/ice.2024.
    PubMed        

  4. VAN REST A, Clarke A, Gounder P, Nie PK, et al
    COVID-19 outbreaks in nursing homes in Los Angeles County, March 2020-April 2022.
    Infect Control Hosp Epidemiol. 2025 Jan 7:1-7. doi: 10.1017/ice.2024.
    PubMed         Abstract available


    J Infect

  5. ONG DS, Harris M, Hart JD, Russell FM, et al
    Lack of correlation between school reopening and trends in adult COVID-19 hospitalisations and death rates during the Delta and early Omicron periods: an ecological analysis of five countries.
    J Infect. 2025 Jan 6:106390. doi: 10.1016/j.jinf.2024.106390.
    PubMed         Abstract available

  6. JORDA A, Prager M, Pracher L, Haselwanter P, et al
    Immunogenicity, Safety, and Reactogenicity of Concomitant Administration of the Novavax Vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent Pneumococcal Conjugate Vaccine in Adults Aged >/=60 Years: A Randomised, Double-blind, Placebo-contro
    J Infect. 2025 Jan 3:106405. doi: 10.1016/j.jinf.2024.106405.
    PubMed         Abstract available


    J Med Virol

  7. ZHANG S, Kong X, Zhen Q, Wei Y, et al
    Dynamic Changes and Trends of SARS-CoV-2 Antibodies Induced by Infection and Vaccination Across Multiple Time Points.
    J Med Virol. 2025;97:e70161.
    PubMed         Abstract available

  8. KO C, Cheng CC, Mistretta D, Ambike S, et al
    SARS-CoV-2 Productively Infects Human Hepatocytes and Induces Cell Death.
    J Med Virol. 2025;97:e70156.
    PubMed         Abstract available


    J Virol

  9. GRIMES SL, Heaton BE, Anderson ML, Burke K, et al
    The coronavirus nsp14 exoribonuclease interface with the cofactor nsp10 is essential for efficient virus replication and enzymatic activity.
    J Virol. 2025 Jan 10:e0170824. doi: 10.1128/jvi.01708.
    PubMed         Abstract available

  10. ARORA P, Zhang L, Nehlmeier I, Kempf A, et al
    Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D.
    J Virol. 2025 Jan 10:e0123024. doi: 10.1128/jvi.01230.
    PubMed         Abstract available

  11. HU H, Leng C, Shu Y, Peng L, et al
    Structural insights into hybridoma-derived neutralizing monoclonal antibodies against Omicron BA.5 and XBB.1.16 variants of SARS-CoV-2.
    J Virol. 2025 Jan 7:e0130724. doi: 10.1128/jvi.01307.
    PubMed         Abstract available

  12. GUNAWARDENE CD, Wong L-YR
    Betacoronavirus internal protein: role in immune evasion and viral pathogenesis.
    J Virol. 2025 Jan 6:e0135324. doi: 10.1128/jvi.01353.
    PubMed         Abstract available


    Life Sci

  13. CHOPRA A, Franko N, Chow EJ
    Navigating neurologic post-COVID-19 conditions in adults: Management strategies for cognitive dysfunction, headaches and neuropathies.
    Life Sci. 2025;362:123374.
    PubMed         Abstract available


    Zhonghua Jie He He Hu Xi Za Zhi

  14. SONG LC, Xie LX
    [Clinical update in critical care of pulmonary medicine 2024].
    Zhonghua Jie He He Hu Xi Za Zhi. 2025;48:84-89.
    PubMed         Abstract available

  15. LI SN, Ni WT, Li R, Chen YW, et al
    [Clinical characteristics of immunocompromised patients infected with COVID-19].
    Zhonghua Jie He He Hu Xi Za Zhi. 2025;48:35-42.
    PubMed         Abstract available


  16. [Chinese expert consensus on the diagnosis and treatment of pneumonia in the elderly (2024 Edition)].
    Zhonghua Jie He He Hu Xi Za Zhi. 2025;48:18-34.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, January 12 '25)

 


    Arch Virol

  1. SAKUMA S, Mine J, Uchida Y, Kumagai A, et al
    Long-term immune responses induced by low-dose infection with high pathogenicity avian influenza viruses can protect mallards from reinfection with a heterologous strain.
    Arch Virol. 2025;170:33.
    PubMed         Abstract available

  2. ARVIA R, Rocca A, Casciato B, Stincarelli MA, et al
    High-resolution melting analysis for detection of nucleotide mutation markers in the polymerase-acidic (PA) gene of influenza virus that are associated with baloxavir marboxil resistance.
    Arch Virol. 2025;170:29.
    PubMed         Abstract available

  3. ASHRAF MA, Raza MA, Imran A, Amjad MN, et al
    Next-generation vaccines for influenza B virus: advancements and challenges.
    Arch Virol. 2025;170:25.
    PubMed         Abstract available

  4. REHMAN Z, Edington K, Jamal Z, Kritz-Wilson A, et al
    The introduction of the SARS-CoV-2 BA.4 lineage into Pakistan.
    Arch Virol. 2025;170:26.
    PubMed         Abstract available


    Biochemistry

  5. LEE E, Rauscher S
    The Conformational Space of the SARS-CoV-2 Main Protease Active Site Loops Is Determined by Ligand Binding and Interprotomer Allostery.
    Biochemistry. 2025;64:32-46.
    PubMed         Abstract available


    BMJ

  6. KAST KA, Sidelnik SA, Nejad SH, Suzuki J, et al
    Management of alcohol withdrawal syndromes in general hospital settings.
    BMJ. 2025;388:e080461.
    PubMed         Abstract available


    Epidemiol Infect

  7. CHANDA MM, Shivachandra SB, Mishra A, Punnoose P, et al
    Unique duck rearing practice in irrigated rice paddy fields driving recurrent H5N1 Avian Influenza outbreaks in two districts of Kerala, India.
    Epidemiol Infect. 2025 Jan 7:1-36. doi: 10.1017/S0950268824001882.
    PubMed        

  8. HUIBERTS AJ, Oosting IJ, de Melker HE, van de Wijgert JHHM, et al
    The effect of SARS-CoV-2 infection and COVID-19 vaccination during pregnancy on neonatal outcomes.
    Epidemiol Infect. 2024;153:e5.
    PubMed         Abstract available


    J Gen Virol

  9. RANDALL RE, Young D, Pisliakova M, Andrejeva J, et al
    Single-cycle parainfluenza virus type 5 vectors for producing recombinant proteins, including a humanized anti-V5 tag antibody.
    J Gen Virol. 2025;106.
    PubMed         Abstract available


    J Infect

  10. MOK CKP, Tang YS, Tan CW, Chong KC, et al
    Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine.
    J Infect. 2024;90:106374.
    PubMed         Abstract available


    J Infect Dis

  11. BILLINGS WZ, Ge Y, Knight JH, Hemme H, et al
    High dose inactivated influenza vaccine inconsistently improves heterologous antibody responses in an elderly human cohort.
    J Infect Dis. 2025 Jan 8:jiaf003. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  12. FOX CR, Yousef NN, Varudkar N, Shiffer EM, et al
    Resistance to complement-mediated lysis of parainfluenza virus 5-infected cells is acquired after transition from acute to persistent infection.
    J Virol. 2025 Jan 10:e0189524. doi: 10.1128/jvi.01895.
    PubMed         Abstract available

  13. PERRY SS, Brice DC, Sakr AA, Kandeil A, et al
    Modulation of cytokeratin and cytokine/chemokine expression following influenza virus infection of differentiated human tonsillar epithelial cells.
    J Virol. 2025 Jan 10:e0146024. doi: 10.1128/jvi.01460.
    PubMed         Abstract available


    PLoS Comput Biol

  14. ABRAHAM AA, Tan ZC, Shrestha P, Bozich ER, et al
    A multivalent binding model infers antibody Fc species from systems serology.
    PLoS Comput Biol. 2024;20:e1012663.
    PubMed         Abstract available

  15. FAJARDO-FONTIVEROS O, Mattei M, Burgio G, Granell C, et al
    Machine learning mathematical models for incidence estimation during pandemics.
    PLoS Comput Biol. 2024;20:e1012687.
    PubMed         Abstract available

  16. ZHANG XY, Yu LL, Wang WY, Sun GQ, et al
    Estimating the time-varying effective reproduction number via Cycle Threshold-based Transformer.
    PLoS Comput Biol. 2024;20:e1012694.
    PubMed         Abstract available

  17. ZUNKER H, Schmieding R, Kerkmann D, Schengen A, et al
    Novel travel time aware metapopulation models and multi-layer waning immunity for late-phase epidemic and endemic scenarios.
    PLoS Comput Biol. 2024;20:e1012630.
    PubMed         Abstract available


    PLoS One

  18. GOLROKHIAN-SANI AA, Morcos M, Philippi A, Al-Rawi R, et al
    Temporal trends in mental health terminology in Alzheimer's disease clinical trials.
    PLoS One. 2024;19:e0310264.
    PubMed         Abstract available

  19. QUINN KL, Stukel TA, Detsky A, Chung H, et al
    Use of virtual care near the end of life before and during the COVID-19 pandemic: A population-based cohort study.
    PLoS One. 2025;20:e0313766.
    PubMed         Abstract available

  20. EVEREST L, Henderson J, Ma C, Prebeg M, et al
    Relationship between mental health and substance abuse on COVID-19 vaccine hesitancy in youth: A mixed methods longitudinal cohort study.
    PLoS One. 2025;20:e0313157.
    PubMed         Abstract available

  21. DZOGAN M, Lacko R, Hajduova Z
    Empirical research of foreign direct investments efficiency in the European Union on the edge of pandemic outbreak.
    PLoS One. 2025;20:e0313161.
    PubMed         Abstract available

  22. TURK F
    Traumatic stress and post-traumatic growth in individuals who have had Covid-19: The mediating effect of resilience and moderating effect of psychological flexibility.
    PLoS One. 2024;19:e0310495.
    PubMed         Abstract available

  23. AMEDEWONU EA, Aryeetey GC, Godi A, Sackeyfio J, et al
    Coping strategies of COVID-19 recovered patients at the Ghana Infectious Disease Centre.
    PLoS One. 2025;20:e0310921.
    PubMed         Abstract available

  24. THONGDEE M, Chaiwattanarungruengpaisan S, Ketchim N, Sangkachai N, et al
    Evidence of avian and human influenza A virus infection in farmed Siamese crocodiles (Crocodylus siamensis) in Thailand.
    PLoS One. 2025;20:e0317035.
    PubMed         Abstract available

  25. HERGOTT M, Andreski M, Rovers J
    Vaccine hesitancy among health paraprofessionals: A mixed methods study.
    PLoS One. 2025;20:e0312708.
    PubMed         Abstract available

  26. SATO Y, Kawachi I, Saijo Y, Yoshioka E, et al
    Correlates of COVID-19 conspiracy theory beliefs in Japan: A cross-sectional study of 28,175 residents.
    PLoS One. 2024;19:e0310673.
    PubMed         Abstract available

  27. PHILLIPS G, Racine E, Naughton AM, Lane J, et al
    Understanding uptake of the COVID-19 vaccination among the homeless: A mixed methods evaluation.
    PLoS One. 2025;20:e0312617.
    PubMed         Abstract available

  28. KRISTENSEN K, Boodram B, Avila W, Pineros J, et al
    Perceptions of access to harm reduction services during the COVID-19 pandemic among people who inject drugs in metropolitan Chicago.
    PLoS One. 2025;20:e0293238.
    PubMed         Abstract available

  29. BRATCHER A, Jones JM, Meyer WA 3rd, Waheed R, et al
    Anti-nucleocapsid SARS-CoV-2 antibody seroprevalence in previously infected persons with immunocompromising conditions-United States, 2020-2022.
    PLoS One. 2025;20:e0313620.
    PubMed         Abstract available

  30. LAARMAN C, Hahne SJ, de Melker HE, Knol MJ, et al
    SARS-CoV-2 risk factors among symptomatic vaccinated adults attending community testing locations in the Netherlands from June 2021 till February 2022.
    PLoS One. 2024;19:e0311229.
    PubMed         Abstract available

  31. KUMAR V, Golzarri-Arroyo L, Roth S, Imperiale TF, et al
    Effect of the COVID-19 pandemic on colorectal cancer screening in two university-affiliated health care systems.
    PLoS One. 2025;20:e0317057.
    PubMed         Abstract available

  32. WAGNER K, Reinhardt Z, Negash S, Weber L, et al
    University students' health-related quality of life and its determinants. Results from a cross-sectional survey during the COVID-19 pandemic.
    PLoS One. 2025;20:e0310378.
    PubMed         Abstract available

  33. MOHAMMAD KM, Akhi AA, Kamrujjaman M
    Bifurcation analysis of an influenza A (H1N1) model with treatment and vaccination.
    PLoS One. 2025;20:e0315280.
    PubMed         Abstract available

  34. PARRY-NWEYE E, Liu Z, Dhaouadi Y, Guo X, et al
    Persistence of Phi6, a SARS-CoV-2 surrogate, in simulated indoor environments: Effects of humidity and material properties.
    PLoS One. 2025;20:e0313604.
    PubMed         Abstract available

  35. PENG A
    Sustainable regional development from the perspective of economic resilience: Based on the impact of COVID-19.
    PLoS One. 2025;20:e0314663.
    PubMed         Abstract available

  36. KAWAHARA M, Tanaka A
    Impact of partial occlusion of the face on multisensory emotion perception: Comparison of pre- and post-COVID-19 pandemic.
    PLoS One. 2025;20:e0307631.
    PubMed         Abstract available

  37. WHITESIDE C, Klabbers G
    Exploring the perceptions of the effect of the COVID-19 pandemic on the mental well-being and medical education of medical students in Northern Ireland, in addition to the perceived barriers to seeking support; a qualitative study.
    PLoS One. 2025;20:e0314115.
    PubMed         Abstract available

  38. BAKER JM, Nakayama JY, O'Hegarty M, McGowan A, et al
    Household transmission of SARS-CoV-2 in five US jurisdictions: Comparison of Delta and Omicron variants.
    PLoS One. 2025;20:e0313680.
    PubMed         Abstract available

  39. O'NEILL L, Chumbler NR
    Examining the risk of delirium in patients hospitalized with COVID-19: Insights from the homeless population.
    PLoS One. 2025;20:e0313242.
    PubMed         Abstract available

  40. BATISTELLA P, Marca L, Vasconcellos FCF, Sanguinet ER, et al
    Determinants of agricultural employment during the COVID-19 pandemic: A spatial analysis of Brazilian municipalities.
    PLoS One. 2025;20:e0316489.
    PubMed         Abstract available

  41. DROST M, Loibl C, Snyder A, Betz M, et al
    The association of financial resources and loneliness among older adults during a state of emergency.
    PLoS One. 2025;20:e0314042.
    PubMed         Abstract available

  42. GRASSI M, Tarantino B
    SEMdag: Fast learning of Directed Acyclic Graphs via node or layer ordering.
    PLoS One. 2025;20:e0317283.
    PubMed         Abstract available

  43. DOMNICH A, Trombetta CS, Fallani E, Salvatore M, et al
    Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0310677.
    PubMed         Abstract available

  44. LENIZ J, Hernandez-Jana S, Soto M, Arenas E, et al
    Association between demographic, clinical characteristics and severe complications by SARS-CoV-2 infection in a community-based healthcare network in Chile.
    PLoS One. 2024;19:e0314376.
    PubMed         Abstract available

  45. BARRETO TO, Farias FLO, Veras NVR, Cardoso PH, et al
    Artificial intelligence applied to bed regulation in Rio Grande do Norte: Data analysis and application of machine learning on the "RegulaRN Leitos Gerais" platform.
    PLoS One. 2024;19:e0315379.
    PubMed         Abstract available

  46. BARNES SJ, Na Y, Drainoni ML, Linas BA, et al
    Barriers and facilitators to conducting human subjects research at a safety net institution from the perspective of researchers.
    PLoS One. 2025;20:e0313530.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  47. SCHULZ S, Tan TJC, Wu NC, Wang S, et al
    Epistatic hotspots organize antibody fitness landscape and boost evolvability.
    Proc Natl Acad Sci U S A. 2025;122:e2413884122.
    PubMed         Abstract available

  48. SINGH R, Im C, Qiu Y, Mackness B, et al
    Learning the language of antibody hypervariability.
    Proc Natl Acad Sci U S A. 2025;122:e2418918121.
    PubMed         Abstract available


    Vaccine

  49. EL SAHLY HM, Anderson EJ, Jackson LA, Neuzil KM, et al
    Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.
    Vaccine. 2025;47:126689.
    PubMed         Abstract available


    Virus Res

  50. DEZORDI FZ, Junior JVJS, Ruoso TF, Batista AG, et al
    Higher frequency of interstate over international transmission chains of SARS-CoV-2 virus at the Rio Grande do Sul - Brazil state borders.
    Virus Res. 2025;351:199500.
    PubMed         Abstract available

  51. EL HOUDI M, Skhoun H, El Fessikh M, Benmansour R, et al
    Association study of the JAK/STAT signaling pathway with susceptibility to COVID-19 in moroccan patient and in-silico analysis of rare variants.
    Virus Res. 2025;351:199509.
    PubMed         Abstract available

Development of avian #influenza A(#H5) virus #datasets for #Nextclade enables rapid and accurate #clade assignment

Abstract

The ongoing panzootic of highly pathogenic avian influenza (HPAI) A(H5) viruses is the largest in history, with unprecedented transmission to multiple mammalian species. Avian influenza A viruses of the H5 subtype circulate globally among birds and are classified into distinct clades based on their hemagglutinin (HA) genetic sequences. Thus, the ability to accurately and rapidly assign clades to newly sequenced isolates is key to surveillance and outbreak response. Co-circulation of endemic, low pathogenic avian influenza (LPAI) A(H5) lineages in North American and European wild birds necessitates the ability to rapidly and accurately distinguish between infections arising from these lineages and epizootic HPAI A(H5) viruses. However, currently available clade assignment tools are limited and often require command line expertise, hindering their utility for public health surveillance labs. To address this gap, we have developed datasets to enable A(H5) clade assignments with Nextclade, a drag-and-drop tool originally developed for SARS-CoV-2 genetic clade classification. Using annotated reference datasets for all historical A(H5) clades, clade 2.3.2.1 descendants, and clade 2.3.4.4 descendants provided by the Food and Agriculture Organization/World Health Organization/World Organisation for Animal Health (FAO/WHO/WOAH) H5 Working Group, we identified clade-defining mutations for every established clade to enable tree-based clade assignment. We then created three Nextclade datasets which can be used to assign clades to A(H5) HA sequences and call mutations relative to reference strains through a drag-and-drop interface. Nextclade assignments were benchmarked with 19,834 unique sequences not in the reference set using a pre-released version of LABEL, a well-validated and widely used command line software. Prospective assignment of new sequences with Nextclade and LABEL produced very well-matched assignments (match rates of 97.8% and 99.1% for the 2.3.2.1 and 2.3.4.4 datasets, respectively). The all-clades dataset also performed well (94.8% match rate) and correctly distinguished between all HPAI and LPAI strains. This tool additionally allows for the identification of polybasic cleavage site sequences and potential N-linked glycosylation sites. These datasets therefore provide an alternative, rapid method to accurately assign clades to new A(H5) HA sequences, with the benefit of an easy-to-use browser interface.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.01.07.631789v1

_____

Comprehensive #Infectome #Analysis Reveals Diverse Infectious Agents with #Zoonotic #Potential in #Wildlife

Abstract

Understanding wildlife-pathogen interactions is crucial for mitigating zoonotic risk. Through meta-transcriptomic sequencing we profiled the infectomes of 1,922 samples from 67 mammalian species across China, uncovering a remarkable diversity of viral, bacterial, fungal, and parasitic pathogens. Of the 195 pathogens identified, 62 were novel, including a bi- segmented coronavirus in diseased lesser pandas, which we propose represents a new genus – Zetacoronavirus. The orders Carnivora and Rodentia exhibited the highest pathogen diversity and were implicated in numerous host-jumping events. Comparative analysis of diseased versus healthy animals revealed a trend of higher pathogen loads in the former, with possible differences in tissue tropisms. In total, 48 zoonotic and 17 epizootic pathogens were identified, with frequent cross-species transmission, emphasizing the potential for emerging public health threats. This study highlights the urgent need for wildlife pathogen surveillance to inform proactive disease management strategies.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.01.09.632079v1

_____

The Channel of Gravelines, Petit Fort - Philippe Georges Seurat (1890)


 Source: WikiArt, https://www.wikiart.org/en/georges-seurat/the-channel-of-gravelines-petit-fort-philippe-1890

Public Domain.

_____

Saturday, January 11, 2025

Respiratory #Shedding of Infectious #SARS-CoV-2 #Omicron #XBB.1.41.1 Lineage among Captive White-Tailed #Deer, #Texas, #USA

Abstract

White-tailed deer (Odocoileus virginianus) have high value for research, conservation, agriculture, and recreation and might be key SARS-CoV-2 reservoirs. In November 2023, we sampled 15 female deer in a captive facility in Texas, USA. All deer had neutralizing antibodies to SARS-CoV-2; respiratory swab samples from 11 deer were SARS-CoV-2–positive by quantitative reverse transcription PCR, and 1 deer also had a positive rectal swab sample. Six of the 11 respiratory swab samples yielded infectious virus; replication kinetics of most samples displayed lower growth 24–48 hours postinfection in vitro than Omicron lineages isolated from humans in Texas in the same period. Virus growth was similar between groups by 72 hours, suggesting no strong attenuation of deer-derived virus. All deer viruses clustered in XBB Omicron clade and demonstrated more mutations than expected compared with contemporaneous viruses in humans, suggesting that crossing the species barrier was accompanied by a high substitution rate.

Source: Emerging Infectious Diseases Journal, https://wwwnc.cdc.gov/eid/article/31/2/24-1458_article

_____

An intranasal, NLC-delivered self-amplifying #RNA #vaccine establishes protective #immunity against pre-pandemic #H5N1 and #H7N9 #influenza

Abstract

Seasonal and pandemic influenzas are continuous threats to human health, requiring rapid development of vaccines to multiple evolving viral strains. New RNA vaccine technologies have the adaptability and manufacturability to facilitate pandemic preparedness but have limited flexibility in their route of administration, reducing the ability to establish local protective immune responses such as respiratory mucosal immunity. Here, we describe monovalent and bivalent self-amplifying RNA (saRNA) vaccines against A/Vietnam/1203/2004 H5N1 and A/Anhui/2013 H7N9. These saRNA vaccines express either H5 or H7 hemagglutinin and are formulated with a nanostructured lipid carrier (NLC) that permits both intramuscular (IM) and intranasal (IN) dosing. In mice, IM vaccination established systemic humoral and cellular responses but no detectable mucosal response, while IN administration induced robust systemic and mucosal immunity. The saRNA-NLC vaccines provided complete protection against morbidity and mortality in ferret challenge models, establishing this intranasally-administered saRNA-NLC vaccine platform as a potential pandemic response tool.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.01.07.631792v1?rss=1

_____

The Q226L #mutation can convert a highly pathogenic #H5 2.3.4.4e virus to #bind #human-type #receptors

Abstract

H5Nx viruses continue to wreak havoc in avian and mammalian species worldwide. The virus distinguishes itself by the ability to replicate to high titers and transmit efficiently in a wide variety of hosts in diverse climatic environments. Fortunately, transmission to and between humans is scarce. Yet, if such an event were to occur, it could spark a pandemic as humans are immunologically naive to H5 viruses. A significant determinant of transmission to and between humans is the ability of the influenza A virus hemagglutinin (HA) protein to shift from an avian-type to a human-type receptor specificity. Here, we demonstrate that a 2016 2.3.4.4e virus HA can convert to human-type receptor binding via a single Q226L mutation, in contrast to a cleavage-modified 2016 2.3.4.4b virus HA. Using glycan arrays, x-ray structural analyses, tissue- and direct glycan binding, we show that L133adelta and 227Q are vital for this phenotype. Thus, whereas the 2.3.4.4e virus HA only needs a single amino acid mutation, the modified 2.3.4.4b HA was not easily converted to human-type receptor specificity.

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.01.10.632119v1?rss=1

_____

#USA, #Michigan: {Oakland County} Health Division: 11 people under health #surveillance after contact with #H5N1 #birdflu infected #poultry

Waterford Township, Mich. – The Oakland County Health Division is monitoring a situation involving highly pathogenic avian influenza (HPAI), commonly known as bird flu, identified in animals at the farm at Hess-Hathaway Park in Waterford Township. 

|--     Eleven individuals who had direct contact with the animals are being         monitored    for 10 days, beginning yesterday. --|

Initially, it was reported that two of the 11 are experiencing flu-like symptoms. Since then, the Health Division has learned that only one individual has symptoms. That person’s influenza test has been collected and results from the state lab are pending.

“The risk of contracting bird flu is very low for the general public, but it’s important to be aware of the disease in the community,” said Oakland County Director of Health and Human Services Leigh-Anne Stafford. “Protect yourself and prevent bird flu by avoiding direct contact with sick or dead birds and wash your hands thoroughly if you come into contact with them.

In response to the discovery of HPAI at the farm at Hess-Hathaway Park, Waterford Township has taken proactive measures. Supervisor Anthony Bartolotta emphasized the township’s commitment to safety.

“Until further notice, portions of the farm will be closed to protect our animals, staff and visitors. However, the rest of Hess-Hathaway Park remains open for community enjoyment,” Bartolotta said. “We appreciate the community’s cooperation, patience and understanding as we work to return our farm to regular operations. We look forward to reopening in the Spring of 2025.”

Residents are encouraged to follow these prevention tips:

-- Avoid direct contact with sick or dead birds and animals.

-- Use recommended personal protective equipment (PPE) if contact is necessary.

-- Refrain from touching surfaces contaminated by bird droppings or bodily fluids.

-- Avoid consuming raw milk or raw milk products.

-- If bird flu is suspected in a domestic flock, contact Michigan Department of Agriculture and Rural Development (MDARD) immediately at 800-292-3939 (daytime) or 517-373-0440 (after hours). Additionally, report cases of unusual or unexplained deaths among wild bird populations by contacting the Michigan Department of Natural Resources at 517-336-5030.

MDARD is closely monitoring and responding to reports of sick domestic birds and HPAI throughout the state.

Contact your health care provider if you’ve had close contact with domestic fowl or wild bird and have bird flu symptoms. 

Bird flu symptoms range from no symptoms to severe disease. Signs and symptoms of bird flu in people may include:

-- Eye redness and irritation (conjunctivitis)

-- Mild fever (100 degrees Fahrenheit or greater) or feeling feverish (fever may not always be present)

-- Cough

-- Sore throat

-- Runny or stuffy nose

-- Muscle or body aches

-- Headaches

-- Fatigue

-- Shortness of breath or difficulty breathing

-- Less common symptoms include diarrhea, nausea or vomiting.

HPAI virus is widespread in wild birds worldwide and detected in domestic poultry and other animals. It can spread in various ways from flock to flock, including by wild birds, through contact with infected animals, by equipment, and on the clothing and shoes of caretakers. 

More information about bird flu can be found on the Health Division’s website at oakgov.com/health or by contacting Nurse on Call at 800-848-5533 or noc@oakgov.com. Nurse on Call is available 8:30 a.m. to 5:00 p.m., Monday through Friday. For up-to-date public health information, follow @publichealthOC on Facebook and X.  

Read the initial alert from MDARD here. For additional bird flu information from the state, click on michigan.gov/birdflu.  

Source: Oakland County Department of Health, https://www.oakgov.com/Home/Components/News/News/1751/591

_____

Friday, January 10, 2025

National #ONEHEALTH #Framework to Address #Zoonotic #Diseases and Advance Public Health #Preparedness in the #USA

Executive Summary 

The first ever National One Health Framework to Address Zoonotic Diseases and Advance Public Health Preparedness in the United States (NOHF-Zoonoses), 2025-2029, establishes a structure to facilitate multisectoral and transdisciplinary coordination, collaboration, and communication across the federal government

Using the One Health approach, the framework addresses zoonotic diseases and other priority One Health issues in the United States (U.S.). 

The One Health approach recognizes the interdependence of the health of humans, domestic and wild animals, plants, and the wider environment (including ecosystems). 

This approach mobilizes multiple diverse sectors, disciplines, and communities to work together to promote well-being and address health and ecosystem threats. 

Previous multisectoral work in the U.S. identified the critical need to formalize federal One Health coordination to address zoonotic diseases and other One Health related issues across the U.S. Government. 

Therefore, in the 2023 Consolidated Appropriations Act and the 2021 House Appropriations Committee Report, Congress directed the Centers for Disease Control and Prevention (CDC) in coordination with other federal agencies, to develop a framework based on the One Health approach to address zoonotic diseases and advance public health preparedness. 

The Act also directed CDC to coordinate with the U.S. Department of Agriculture (USDA) and the Department of the Interior (DOI) to develop a mechanism to support coordination at the federal level related to prevention, detection, control, and response for zoonotic diseases and related One Health activities. 

The One Health approach applies to zoonotic diseases as well as many other health threats at the interconnection between people, animals, plants, and the environment.  

While the primary focus of the NOHF-Zoonoses is addressing zoonotic diseases and advancing public health preparedness, the U.S. OHCU has also incorporated other components of One Health into this framework. 

To meet these directives CDC partnered with DOI, USDA and other federal agencies beginning in November 2021, to plan the establishment of the United States One Health Coordination Unit (U.S. OHCU) and to draft the NOHFZoonoses. 

The U.S. OHCU was launched in January 2024, with joint leadership from CDC (Chair 2024-2026), DOI, and USDA.  

The U.S. OHCU is coordinated by a Chair that will rotate between CDC, USDA, and DOI on a biennial calendar year basis. 

U.S. OHCU membership includes 24 agencies related to health, agriculture, interior, wildlife, environment, development, state, commerce, defense, security, and other fields. 

The draft NOHF-Zoonoses was published in September 2023 via the Federal Register Notice process, to engage and obtain input from state, Tribe, local, and territorial (STLT), non-governmental partners, and the public.  

The NOHF-Zoonoses presents goals and objectives for application of the One Health approach to protect people, animals, and our shared environment in the U.S. from zoonotic diseases and advance public health preparedness to optimize health, food safety and security, and sustainability while also promoting biodiversity and conservation outcomes. 

The NOHF-Zoonoses was designed to align with and complement existing U.S. initiatives that incorporate the One Health approach. 

The seven goals outlined in the NOHF-Zoonoses include the following areas: 

-- (1) Coordination, Collaboration and Communication; 

-- (2) Prevention

-- (3) Preparedness

-- (4) Coordinated Outbreak Investigation, Response, and Recovery; 

-- (5) Surveillance

-- (6) Laboratory; and 

-- (7) Workforce

While this framework focuses on One Health coordination at the federal level, its success depends on robust partnerships with STLT, non-governmental organizations, academia, and private sector partners as well as collaboration with relevant international partners. 

Knowledge and best practices from the implementation of the NOHF-Zoonoses will inform future One Health priorities and strengthen the nation’s ability to address One Health threats and promote health, safety, security, and resilience at the human-animal-plant-environment interface. 

Advancing One Health collaboration in the U.S. through the U.S. OHCU and the NOHF-Zoonoses will enhance our ability to jointly prevent, detect, and respond to zoonotic disease threats and related One Health issues. This initiative will improve efficiency across the U.S. government by enhancing collaboration across all relevant sectors with governmental and non-governmental partners while optimizing resource use in order to protect the health, safety, and security of people, animals, plants, and our shared environment.

(...)

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/one-health/media/pdfs/2025/01/354391-A-NOHF-ZOONOSES-508_FINAL.pdf

_____

Modulation of #cytokeratin and #cytokine/chemokine expression following #influenza virus infection of differentiated #human #tonsillar epithelial cells

ABSTRACT

The tonsils have been identified as a site of replication for Epstein–Barr virus, adenovirus, human papillomavirus, and other respiratory viruses. Human tonsil epithelial cells (HTECs) are a heterogeneous group of actively differentiating cells. Here, we investigated the cellular features and susceptibility of differentiated HTECs to specific influenza viruses, including expression of avian-type and mammalian-type sialic acid (SA) receptors, viral replication dynamics, and the associated cytokine secretion profiles. We found that differentiated HTECs possess more abundant α2,3-linked SA (preferentially bound by avian influenza viruses) than α2,6-linked SA (preferentially bound by mammalian strains). This dual receptor expression suggests a role in influenza virus adaptation and tropism within the tonsils by facilitating the binding and entry of multiple influenza virus strains. Our results indicated the susceptibility of differentiated HTECs to a wide range of influenza viruses from human, swine, and avian hosts. Virus production for most strains was detected as early as 1 day post-infection (dpi), and typically peaked by 3 dpi. However, pandemic H1N1 virus showed remarkably delayed replication kinetics that did not peak until at least 7 dpi. Notably, influenza virus infection impacted the expression of cytokeratins in HTEC cultures, which correlated with altered cytokine secretion patterns. These patterns varied within the strains but were most distinct in swine H3N2 infection. In conclusion, differentiated HTECs exhibited a strain-specific pattern of influenza virus replication and innate immune responses that included changes in cytokeratin and cytokine expression. These studies shed light on the complex interplay between influenza viruses and host cells in the tonsils.

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.01460-24?af=R

_____

#Cambodia records 1st #human #death from #H5N1 in 2025

PHNOM PENH, Jan. 10 (Xinhua) -- A 28-year-old man from southeast Cambodia's Kampong Cham province died of H5N1 human avian influenza on Friday, becoming the first death in 2025, the Ministry of Health said in a press statement.

"Laboratory results from the National Institute of Public Health showed on Jan. 9, 2025 that the man was positive for H5N1 virus," the statement said.

"Although our team of doctors had provided him intensive care, the patient died on Jan. 10, 2025 due to his severe condition, with the symptoms of fever, cough, and dyspnea," it added.

The patient lived in village 22 in Chamkar Leu district's Chamkar Andoung commune.

"According to queries, the patient raised and fed chicken, and he cooked sick chicken for food," the statement said.

Health authorities are looking into the source of the infection and are examining any suspected cases or people who have been in contact with the victim in order to prevent an outbreak in the community, it added.

H5N1 influenza is a flu that normally spreads between sick poultry, but it can sometimes spread from poultry to humans, and its symptoms include fever, cough, runny nose, and severe respiratory illness.

The Ministry of Health called on people to be extra vigilant and not to eat ill or dead poultry, saying that bird flu still poses a threat to people's health.

From 2003 to date, there were 73 cases of human infection with H5N1 influenza, including 44 deaths in the Southeast Asian country, according to the ministry.

Source: Xinhua, https://english.news.cn/asiapacific/20250110/b1035982821244e2828ae53394c1129f/c.html

_____

#Belgium - #Influenza A #H5N1 viruses of high pathogenicity (Inf. with) (non-poultry including wild birds) (2017-) - Immediate notification

 A wild sanderling in Oostende.

Source: WOAH, https://wahis.woah.org/#/in-review/6175

_____

#Human #Health #Surveillance During Animal #Disease #Emergencies: #Minnesota Department of Health Response to Highly Pathogenic Avian #Influenza Outbreaks, 2015 and 2022–2023

ABSTRACT

Objectives

Highly pathogenic avian influenza (HPAI) poses an occupational risk for poultry workers, responders, and others in contact with infected birds. The objective of this analysis was to describe HPAI surveillance methods and outcomes, and highlight the challenges, successes, and lessons learned during the Minnesota Department of Health’s (MDH’s) public health response to HPAI outbreaks in Minnesota poultry flocks in the years 2015 and 2022–2023.

Methods

During both outbreaks, MDH staff attempted to contact all potentially exposed people and conduct a standardized interview. People were considered exposed and at risk if they had entered a barn with poultry on any HPAI test-positive premises. With their consent, exposed persons were entered into illness monitoring until 10 days from their last exposure. In 2015, MDH monitored the health of poultry workers only. In the 2022–2023 response, MDH monitored the health of poultry workers, backyard flock owners, responders, and private contract workers. In 2022–2023, interview responses were entered into a REDCap (Research Electronic Data Capture) database in real time, which automatically entered the person into monitoring if they consented. Through REDCap, they received an automated email with a unique link to a short survey asking about any symptom development. Where appropriate, interview responses from poultry workers collected in 2015 were compared to interview responses from poultry workers collected in 2022–2023.

Results

From March 3 to June 5, 2015, MDH epidemiologists interviewed and evaluated 375 (86%) of 435 poultry workers from 110 HPAI-infected flocks. From March 25, 2022 through December 31, 2023, MDH epidemiologists interviewed and evaluated 649 (65%) of 992 poultry workers, responders, contractors, and backyard flock owners associated with 151 HPAI-infected flocks. Among poultry workers, self-reported personal protective equipment (PPE) usage declined significantly from 2015 to 2022–2023 (full PPE usage 51.8% vs. 23.9%, p < .01).

Conclusion

MDH’s long standing relationships with animal health officials and the poultry industry resulted in strong poultry worker participation rates in surveillance efforts during HPAI outbreaks in 2015 and 2022–2023. Self-reported PPE usage was low, particularly in 2022–2023. Improvements in PPE accessibility and technology are needed to protect workers and responders in the on-going HPAI outbreak.

Source: Journal of Agromedicine, https://www.tandfonline.com/doi/full/10.1080/1059924X.2024.2442406

_____

Testing of #Retail #Cheese, #Butter, Ice Cream, and Other Dairy #Products for Highly Pathogenic Avian #Influenza in the #US

Abstract

The recent outbreak of highly pathogenic avian influenza (HPAI) in dairy cows has created public health concerns about the potential of consumers being exposed to live virus from commercial dairy products. Previous studies support that pasteurization effectively inactivates avian influenza in milk and an earlier retail milk survey showed viral RNA, but no live virus could be detected in the dairy products tested. Because of the variety of products and processing methods in which milk is used, additional product testing was conducted to determine if HPAI viral RNA could be detected in retail dairy samples, and for positive samples by quantitative real-time RT-PCR (qRT-PCR) further testing for the presence of live virus. Revised protocols were developed to extract RNA from solid dairy products including cheese and butter. The solid dairy product was mechanically liquified with garnet and zirconium beads in a bead beater diluted 1–4 with BHI media. This preprocessing step was suitable in allowing efficient RNA extraction with standard methods. Trial studies were conducted with different cheese types with spiked-in avian influenza virus to show that inoculation of the liquified cheese into embryonating chicken eggs was not toxic to the embryos and allowed virus replication. A total of 167 retail dairy samples, including a variety of cheeses, butter, ice cream, and fluid milk were collected as part of a nationwide survey. A total of 17.4% (29/167) of the samples had detectable viral RNA by qRT-PCR targeting the matrix gene, but all PCR-positive samples were negative for live virus after testing with embryonating egg inoculation. The viral RNA was also evaluated by sequencing part of the hemagglutinin gene using a revised protocol optimized to deal with the fragmented viral RNA. The sequence analysis showed all viral RNA-positive samples were highly similar to previously reported HPAI dairy cow isolates. Using the revised protocols, it was determined that HPAI viral RNA could be detected in a variety of dairy products, but existing pasteurization methods effectively inactivate the virus assuring consumer safety.

Source: Journal of Food Protection, https://www.sciencedirect.com/science/article/pii/S0362028X24002151?via%3Dihub

_____

My New Space

Most Popular Posts